Source: Expert Review of Anticancer Therapy. Unidade: FCF
Subjects: FARMACOTERAPIA, NEOPLASIAS
ABNT
MORAES, Francisco Cezar Aquino de et al. Concomitant use of H1 antihistamines improves survival outcomes in cancer patients on immune checkpoint inhibitor therapy: a systematic review and meta-analysis. Expert Review of Anticancer Therapy, v. 21, p. 1-11, 2026Tradução . . Disponível em: https://dx.doi.org/10.1080/14737140.2026.2617952. Acesso em: 25 abr. 2026.APA
Moraes, F. C. A. de, Wagner, P. H. de S., Hirata, R. D. C., Burbano, R. M. R., & Hirata, M. H. (2026). Concomitant use of H1 antihistamines improves survival outcomes in cancer patients on immune checkpoint inhibitor therapy: a systematic review and meta-analysis. Expert Review of Anticancer Therapy, 21, 1-11. doi:10.1080/14737140.2026.2617952NLM
Moraes FCA de, Wagner PH de S, Hirata RDC, Burbano RMR, Hirata MH. Concomitant use of H1 antihistamines improves survival outcomes in cancer patients on immune checkpoint inhibitor therapy: a systematic review and meta-analysis [Internet]. Expert Review of Anticancer Therapy. 2026 ; 21 1-11.[citado 2026 abr. 25 ] Available from: https://dx.doi.org/10.1080/14737140.2026.2617952Vancouver
Moraes FCA de, Wagner PH de S, Hirata RDC, Burbano RMR, Hirata MH. Concomitant use of H1 antihistamines improves survival outcomes in cancer patients on immune checkpoint inhibitor therapy: a systematic review and meta-analysis [Internet]. Expert Review of Anticancer Therapy. 2026 ; 21 1-11.[citado 2026 abr. 25 ] Available from: https://dx.doi.org/10.1080/14737140.2026.2617952

